Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE To analyze adherence to follow-up over 5 years in patients treated with intravitreal ranibizumab for exudative age-related macular degeneration (AMD) in a tertiary health care center. To investigate factors associated with failure to continue follow-up. METHODS Retrospective chart review of all consecutive patients with exudative AMD, who received their first intravitreal ranibizumab injection at the Créteil Intercommunal University Hospital Eye Clinic between October 1, 2006 and March 31, 2007. Patient clinical characteristics at baseline and at the last follow-up visit were recorded. Distance from home to hospital was measured for each patient. A multiple-choice telephone survey was conducted for patients lost to follow-up to determine the main reasons for failure to continue follow-up. RESULTS Two hundred and one patients were included. The rate of loss to follow-up over the 5-year period was 57% (115/201). Fifty-eight patients lost to follow-up completed the questionnaire. The main reasons reported by patients for follow-up discontinuation were long distance from home to hospital (51.7%, 30/58), subjective dissatisfaction with the benefits of intravitreal injections (34.5%, 20/58), and the excessive burden of periodic follow-up visits (24.1%, 14/58). Three factors were significantly associated with follow-up discontinuation: high age at baseline (82.2 vs. 76.5 years, P<0.001), poor best-corrected visual acuity (BCVA) at baseline (42.5 vs. 51.0 letters, P=0.020), and long distance from home to hospital (132 vs. 17.1km, P<0.001). CONCLUSION In this study, adherence to follow-up over 5 years was poor. Age and BCVA at baseline and distance from home to hospital were independently associated with long-term adherence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822
Cited by
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Lanzetta, P., Korobelnik, J.-F., Heier, J. S., Leal, S., Holz, F. G., Clark, W. L., Eichenbaum, D., Iida, T., Xiaodong, S., Berliner, A. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00063-1 · Cited by 266
Grishanin, R., Vuillemenot, B., Sharma, P., Keravala, A., Greengard, J., Gelfman, C., Blumenkrantz, M., Lawrence, M., Hu, W., Kiss, S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.003 · Cited by 127
Monés, J., Singh, R. P., Bandello, F., Souied, E., Liu, X., & Gale, R. (2020) · Ophthalmologica · doi:10.1159/000502747 · Cited by 110
Self-citationGelfman, C. M., Grishanin, R., Bender, K. O., Nguyen, A., Greengard, J., Sharma, P., Nieves, J., Kiss, S., & Gasmi, M. (2021) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2021.0001 · Cited by 55
Metadata
- Authors
- Boulanger-Scemama, E., Querques, G., About, F., Puche, N., Srour, M., Mane, V., Massamba, N., Canoui-Poitrine, F., & Souied, E. H.
- Venue
- Journal Français d'Ophtalmologie
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 38
- Issue
- 7
- Pages
- 620-627
- ISSN
- 0181-5512 (ISSN-L)
- OpenAlex
- W2007177737
- Cited by
- 124
- References
- 4
- FWCI
- 6.37
- Type
- journal article
- Language
- fr
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting. https://app.cochat.ai/papers/10.1016/j.jfo.2014.11.015
- The paper
- Boulanger-Scemama, E., Querques, G., About, F., Puche, N., Srour, M., Mane, V., Massamba, N., Canoui-Poitrine, F., & Souied, E. H. (2015). Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting. Journal Français d'Ophtalmologie. https://doi.org/10.1016/j.jfo.2014.11.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.